TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: A multicenter, single-arm, phase 2 clinical study evaluated BV retreatment in adults with relapsed/refractory cHL or CD30-expressing PTCL who received an initial BV regimen ≥ 6 months pre-study enrollment and had an objective response followed by disease progression/relapse [8].